A Catalytic
Starting Line
2013 Annual ReportB r i n g i n g J a p a n e s e i n n o va t i o n ,i n v e s t m e n t, a n d l e a d e r s h i p t o
the global fight against
infectious diseases

The GHIT Fund is a public-private partnership of over
US$100 million between five Japanese pharmaceuticalcompanies (Astellas Pharma Inc., Daiichi Sankyo & Co.
Ltd., Eisai, Shionogi & Co. Ltd., and Takeda Pharmaceutical
Company Ltd.), two Japanese government ministries(Ministry of Foreign Affairs and Ministry of Health, Labourand Welfare), the Bill & Melinda Gates Foundation, andthe United Nations Development Programme.

Copyright © 2014 by the Global HealthInnovative Technology (GHIT) Fund.
All rights reserved.

CONTENTS
L e t t e r f r o m t h e B o a r d C h a i r a n d CEO

O u r L a u n c h Pa d

Milestones and First Fruits

Finances

Leadership

Pa r t n e r s

1

Global strides,
bold firsts
The GHIT Fund’s inaugural year was one of significant firsts: our first grant investments, our firstgroundbreaking partnerships, and the launch of our screening and hit-to-lead platforms designed
to jump-start drug discovery. The establishment of the GHIT Fund also represents important firsts
for advancing global health and collaboration more broadly:

The ﬁrst public-private partnership for global health R&D funding.
The first time that a group of pharmaceutical companies has joined together to initiate a major
fund—and invested directly—to facilitate and advance global health R&D.

The first time that the Japanese government has significantly invested in global health R&D.
These firsts are exciting, and the promise they hold to transform global health is humbling. Our
partners are driven by the conviction that advancing the development of new healthcare technologies

is not only a responsibility, but also a long-term investment—one that carries significant returns

for Japan’s future. They see that future as firmly tied to the growth of healthy populations andeconomies in the developing world.

The Japanese government and the country’s leading pharmaceutical companies, together with theBill & Melinda Gates Foundation and the United National Development Programme (UNDP),

have launched something entirely new. Their foresight, personal engagement, and commitment

inspire our team as we continue to work toward our goal of achieving the most important firsts:
cost-effective healthcare tools to reduce the burden of disease in the world’s poorest countries.
We are honored to share our first annual report of progress with you.

2

Kiyoshi Kurokawa, MD

BT Slingsby, MD, PhD, MPH

Chair of the Board

Chief Executive Officer

“ We w e l c o m e t h e G H IT F u n d’s i n v e s t m e n t a n dcollaboration in the globa l f ight aga inst diseases thatd i s p r o p o r t i o n a t e l y a f f e c t t h e p o o r e s t o f t h e p o o r. . . .
T h is com m it ment of add it iona l resou rces for

R & D m ov e s u s a b i g s t e p c l o s e r t o t h e g o a l o fcont rol l i ng a nd defeati ng t hese neglectedd iseases a nd t he vast hu ma n m iser y t hey
c a u s e.”

M a rg a r e t C ha n,
D ir e ctor- G e n e r a l ,World H e a lth O rg a n i z atio n3

O u r L a u n c h Pa d

A legacy of innovation and overseas aid
The GHIT Fund was conceived in 2011 by Japan’s pharmaceutical industry, whose leaders sought to tap
into Japan’s legacy of global leadership in drug development, technological innovation, and overseas development
assistance (ODA) to create a public-private partnership fund for global health R&D.
While Japan has long been the number three global leader in drug development, and a critical ODA
provider, the country had yet to realize its potential in the development of technology specifically for global
health.
The pharmaceutical industry recognized that harnessing Japan’s considerable resources, expertise, andinnovation in the creation of new medicines, vaccines, and diagnostics for diseases that impact the poorest
populations would require global partnerships.

Global alignment toward critical “firsts” in global health R&D
Neglected Tropical Diseases (NTDs), along with

development partnerships (PDPs) to push forward

HIV/AIDS, malaria, and tuberculosis (TB) affectinnovations for these diseases—innovations that arenearly 40% of the world’s population and have thedesperately needed but have not been developed due

most unmet medical needs. NTDs often result in

to a lack of commercial investment.

delayed growth in children; permanent disabilities,
such as organ damage and blindness; and even death.
Repeated bouts of illness prevent families fromworking, trapping entire communities in an endlesscycle of poverty.
Over the past 60 years, the global healthcommunity has aligned through the World HealthOrganization (WHO), UN agencies, major foundations
such as the Bill & Melinda Gates Foundation and theWellcome Trust, and the establishment of product4

Overall funding for NTDs hasremained static since 2009. In cases
where tools are available, they arein very short supply. The GHIT Fundinjects critical new funding and newtechnology into global health R&D.

Japan’s recent first-hand experience with disease and poverty
Japan deeply appreciates the importance ofthan 35 years, the country became the number two

working in solidarity to address the world’s global

economy in the world and home to myriad multinational

health challenges. In post-war Japan, disease

corporations, technology innovators, and politicalepidemics, undernutrition, and poverty were part ofleaders. In that same period of time, Japan—for whichdaily life. Malaria, TB, and NTDs were endemic. But

TB had been a “national scourge”—became the nationa nationwide community-based program resulted inwith the highest global life expectancy. Today, thethe effective elimination and subsequent eradication

public health programs of postwar Japan form theof these diseases in Japan. Transformational healthbasis of many WHO disease elimination strategies.

gains led to enormous economic development. In lessWith recent first-hand experience
with the interconnectedness between
health and economic development,
Japan and its people remain committed
to supporting other countries in theirquest for similar success.

5Political will and new policy engagement
In 2013, the Japanese government made global health a central component of its foreign policy anddomestic economic revitalization strategy, demonstrating its recognition of global health as not only an ODA
target but also a critical factor in national human security. This policy shift serves as a milestone in a yearslong intensification of efforts to more effectively support R&D and leverage the country’s deep well oftechnology and innovation in order to maximize the value of its foreign aid.
The Japanese government’s investment in the GHIT Fund is a direct realization of the country’s 2013
Strategy on Global Health Diplomacy, which encourages strategic collaborations with international partners
and the use of domestic R&D capabilities in continued support of achieving the UN’s Millenium Development
Goals (MDGs). This strategy is linked tightly with Japan’s Healthcare and Medical Strategy, also launchedin 2013.
Policy engagement in global health at the highest levels of the Japanese government complement thecountry’s legacy of important investments in health: Japan helped establish the Global Fund and put healthon the G8 agenda, and the country has contributed to the achievement of MDGs for years. The formalizationof foreign policy focused on combating the most devastating diseases of the developing world has been under
way since the mid-1990s, along with an increasing recognition of the overwhelming toll that infectious diseases
take on the communities and economies Japan’s ODA supports.

M ILEST O NES

•
•

•
•

Institutional launch
1st call for proposals
for collaborative R&D,
including pre-clinicalresearch (post-lead
optimization) throughlicensure

April 20136•

Drug Discovery Screening
Platform established
1st call for proposals forscreening partnerships
announced
13 partnerships establishedbetween Japaneseentities and international
collaborators to work on
chemical compounds for
drug discovery for malaria,
TB, and NTDs

June 2013

2nd RFP for collaborative R&D•

2nd call for
proposalsannounced

August 2013

•
•

•

US$5,450,975 (¥560,469,256)
invested for six grants forpartnerships working on drugs
and vaccines against malaria, TB,
and Chagas’ disease
Hit-to-Lead Platform launched
2nd call for proposals for• Hit-to-Lead Platform
screening partnerships
launched
announced

November 2013

February 2014

US$12,107,156(¥1,244,857,831) invested
for four grants to speed
the development ofinnovative drugs for
schistosomiasis, Chagas’
disease, and parasitic
roundworms, as well as
research on a novel TB
vaccine candidate

March 20147

First Fruits

T h e G H I T F u n d h a s f a cilit at e d o v e r 2 0 R & D p a rt n e rships
to a d va n c e product d e v e lopm e n t usi n g J a p a n e s e
i n n o vatio n . H ighlights of thr e e such p a rt n e rships a n dour scr e e n i n g pl atform i n clud e th e followi n g :Pediatric Formulation of the Gold Standard Drugfor Schistosomiasis
ASTELLAS PHARMA INC.

Astellas Pharma’s innovative pharmaceutical

FARMANGUINHOS

technologies in drug formulation and clinical development

MERCK KGAA

for children enables this partnership to create a pediatric

SIMCYP LTD.
SWISS TROPICAL & PUBLICHEALTH INSTITUTE
TOP INSTITUTE PHARMA

formulation for praziquantel, the gold standard drug
co-developed by Merck KGaA and Bayer in the mid1970s. Leveraging the Swiss Tropical and Public Health’s
expertise on drug effectiveness and efficiency in endemic

INN O V A TI O N
CH A LLENGE

regions, the fruits of this collaboration will change theWith the standard
recommended treatment,
younger children run asignificant risk of choking
because of the sizeand bitter taste of theoral tablets. A pediatricformulation is urgently
needed to increasesafety, acceptability,
and overall access.

game dramatically for schistosomiasis treatment.
The partnership has already produced test batchesof two new pediatric drug formulations, which will betested first in adults, followed by taste tests for children.
Support from the GHIT Fund not only accelerates thisproject’s progress, but it also helps the partnership prepare
for Phase II studies with the new formulation selected
for further development.

“The Consor tium, with its 6 par tners, is commit ted to contribute to the elimination of
the second-most prevalent tropical disease in Africa through Astellas’ exper tise inad vanced f ormula tion technology and development. We believe the par tner ship with
GHIT is the key for success to accelerate and expand our activities in deliveringt r e a t m e n t t o t h e v e r y y o u n g c h i l d r e n s u f f e r i n g f r o m s c h i s t o s o m i a s i s .”Yo s h i h i k o H a t a n a k a , R e p r e s e n t a t i v e D i r e c t o r, P r e s i d e n t a n d C E O , A s t e l l a s P h a r m a I n c .

SCHISTOSOMIASIS
Schistosomiasis (or bilharzia) spreads through parasitic worms and can lead to anemia, stunting,
reduced learning ability, and death. Endemic in 78 countries, it affects more than 240 million
people (40% of them children), making it second only to malaria in impact of a parasitic disease.
Annual global economic losses due to schistosomiasis are estimated at more than US$640 million.
8

A Novel TB Vaccine“Early research shows tremendous potential for the
rhPIV2 platform. This par tnership helps to bring the

AERAS

global health communit y closer to the ultimate goal

CREATE VACCINE CO., LTD.

of establishing a new vaccine strategy for the

NATIONAL INSTITUTE OF
BIOMEDICAL INNOVATION OF
JAPAN (NIBIO)p r e v e n t i o n o f T B .”Y a s u h i r o Y a s u t o m i , D i r e c t o r,
Ts u k u b a P r i m a t e R e s e a r c h C e n t e r, N I B I O

combines advanced science and technology created in Japan withtranslational R&D expertise from Create Vaccine (a joint venture
between Dainippon Sumitomo Pharma and Japan BCG Laboratory)
and Aeras. The partnership will advance vaccine candidates basedon the rhPIV2 technology created by the Tsukuba Primate ResearchCenter at NIBIO through preclinical stages, with the goal ofadvancing to safety and immunogenicity testing in clinical trials.

The only TB vaccine
available today (BCG) was
developed more than 90
years ago and provides
insufficient protection
to teenagers and adults,
who carry the highest TB
burden.

INN O V A TI O N
CH A LLENGE

This collaboration—made possible by GHIT support—

Partners are establishing development criteria, including
characterizing new vaccine constructs with a variety of antigens,the conduct of immunology studies to identify the most promisingnovel vaccines, and the establishment of good manufacturing
practices.

TUBERCULOSIS
According to the WHO, in 2012, 8.6 million people fell ill with TB and 1.3 million died from TB. TB
takes the greatest toll on individuals during their most productive years (ages 15 to 44). Annual
global costs for TB treatment and care are estimated at US$8 billion. The global emergence andspread of multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) impose
enormous human and economic costs—more than 200 times the cost of treating drug-susceptible TB.
9

Accelerating the Development of Novel Drugs
for Malaria

MEDICINES FOR MALARIAVENTURES (MMV)
TAKEDA PHARMACEUTICAL
CO., LTD.

This partnership—catalyzed by the GHIT
Fund— brings Takeda’s unique chemistry expertiseand know-how in clinical testing together withpromising MMV compounds to advance new
antimalarial drug candidates. One drug is DSM265,

INN O V A TI O N
CH A LLENGE

which kills the malaria parasite through inhibition
Emerging resistance to the few
widely used antimalarial drugs
in our arsenal has resulted
in increasingly complicatedtreatment challenges. With no new
drug class yet on the market, thegains made thus far in controllingand eliminating malaria arebeing severely threatened.

of an essential enzyme and has already entered
Phase I studies. It has so far shown a good safety
profile, and the compound’s long duration of action
creates the potential for DSM265 to be part of asingle-dose cure.
Another drug is ELQ300, a preclinicalantimalarial prophylactic quinolone derivative.
This antimalarial compound is in earlier stagesof development, and research to date indicates that
ELQ300 has the potential to be given once a month“ I t i s a n h o n o r t o p a r t n e r w i t h Ta k e d a .
This collaboration provides MMV withaccess to novel Japanese compounds,
expertise, and support, which we hopeto treat and prevent malarial infections, which
would make it an important tool for low-dose curesor prophylaxis of the disease. However, somewill open the door to new breakthroughadditional work related to its formulation is needed

malaria medicines to help stop

before it can be tested in patients. Here, Takeda

unnecessar y loss of life due to thedisease and pave the way for malaria
e l i m i n a t i o n a n d e r a d i c a t i o n .”David Redd y, CEO, MM V

is contributing critical chemistry, manufacturing,and controls expertise for the development of asolid oral dose form development.

Malaria
Malaria causes more than 200 million cases and approximately 650,000 deaths annually, 86% ofthem among children. In some endemic countries, the disease accounts for up to 40% of publichealth expenditures, 30-50% of inpatient hospital admissions, and up to 60 percent of outpatient
health clinic visits. This disease costs Africa between US$12-30 billion in lost GDP every year.

10Why partnerships for
product development?
Global health challenges are too great for one
pharmaceutical company, research institution, or nation toconfront alone.
Consider a billion people who are in desperate need of new drugs, vaccines, anddiagnostics, but they can’t pay—or can pay only pennies. Now reflect on the factthat the creation of these tools requires massive investments of capital, time, andcomplex R&D. Combine scientific complexity and enormous risk with uncertainty
around the adoption and uptake of these tools due to poor infrastructure in thecommunities that need them most, and we have the equation for the dearth of
new drugs for the diseases that affect the world’s poorest.
Partnerships for product development are indispensible to the discovery
and development of new technologies for diseases that have little or nocommercial market. These partnerships often take place between the public
sector, industry, academia, and international agencies—leveraging eachorganization’s strengths while acknowledging and addressing their needs
and constraints. Similar to the GHIT Fund, partnerships for productdevelopment often use public and philanthropic funds to reduce orremove risk for companies and research institutions undertaking
the R&D. The results of these partnerships: quicker, less costly
development of badly needed, affordable health tools
with game-changing global health benefits.

11

URGENCY
The early-stage drug pipeline for malaria, TB, leishmaniasis, and Chagas’ disease is nowhere near as
robust as it should be, considering the health and economic burdens these diseases carry, as well as
the number of products that the global community is trying to develop. To secure a stable pipeline,
new chemical entities and novel compounds are critical.

12

Drug Discovery Screening Platform
Expanding the drug pipeline for neglected diseases

global innovator in new chemical entities—the essenceof what makes drugs effective. Countless chemical

Japan’s unique chemicalcompounds, whose structuresdiffer significantly from thosefound in the West, bring new
resources, chemistry, andpromise to the fight against
infectious disease.

entities with enormous potential for developing new
tools to combat the major diseases of the developingworld sit on the shelves of Japan’s public and private
research institutions.
In June 2013, for the first time, Japan’s private and

INN O V A TI O NO PP O RTUNITY

Japan’s pharmaceutical sector is a long-establishedacademic sectors opened the doors of their vast,advanced compound libraries to PDPs through the
GHIT Fund’s Drug Discovery Screening Platform.

In February 2014, the GHIT Fund launched its

These PDPs are focused on drug discovery for TB,

Hit-to-Lead Platform with the goal of converting drug

malaria, leishmaniasis, and Chagas’ disease. This will“hits” identified through the Screening Platform into

enable the screening of tens of thousands of drug

“lead compounds”—chemicals that show promise as

candidates for potential new treatments. Initialanti-infectives but likely require further chemical

partnerships have already begun screening chemical

modification before they can be tested as human drugs.

compounds from Japanese partner libraries with assays

This new program will help researchers find promising

for target diseases and assessing their impact on

drug compounds that can fight deadly and debilitating

parasites and bacteria of focus.

infectious diseases.

The Partners

The Libraries

ALLIANCE FOR TB DRUG
DEVELOPMENT

PrivateASTELLAS PHARMADAIICHI SANKYOEISAISHIONOGI
TAKEDADRUGS FOR NEGLECTEDDISEASES INITIATIVE (DNDI)
MMVAcademic
INSTITUTE OF MICROBIALCHEMISTRYKITASATO INSTITUTE

13

LFINANCES
eadership***Translation***Independent Auditor’s Report
To the Board of Directors, Global Health Innovative Technology Fund:We have audited the accompanying financial statements, which comprise the balance sheet, the statement of income,the notes to the financial statements, and the related supplementary schedules of the General Incorporated Association
Global Health Innovative Technology Fund (“the Organization”) applicable to the second fiscal year from April 1, 2013,
through March 31, 2014. We conducted our audit in accordance with the rules and regulations concerning General
Incorporated Associations and General Incorporated Foundations in Japan, under Item 1 in Paragraph 2 of Article 124.
Directors’ Responsibility for the Financial Statements and the Related Supplementary Schedules
Directors need to ensure that the financial statements and related supplementary schedules were prepared and fairly
presented in accordance with accounting principles generally accepted in Japan. Among others, directors are responsiblefor designing and operating such internal control as directors determine is necessary to enable the preparation and fairpresentation of the financial statements and the related supplementary schedules that are free from material misstatement,
whether due to fraud or error.
Auditor’s Responsibility
Our responsibility is to express an opinion on these financial statements and the related supplementary schedules basedon our audit. We conducted our audit in accordance with auditing standards generally accepted in Japan. Those standards
require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements andthe related supplementary schedules are free from material misstatement.
An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial
statements and the related supplementary schedules. The procedures selected depend on the auditor’s judgment, including
the assessment of the risks of material misstatement of the financial statements and the related supplementary schedules,
whether due to fraud or error. The purpose of an audit of the financial statements is not to express an opinion on theeffectiveness of the Organization’s internal control, but in making these risk assessments, the auditor considers internal
controls relevant to the Organization’s preparation and fair presentationof the financial statements in order to design audit procedures that areappropriate for the circumstances. An audit also includes evaluating
the appropriateness of accounting policies used and the reasonablenessof accounting estimates made by directors, as well as evaluating theoverall presentation of the financial statements and the related
supplementary schedules.
We believe that the audit evidence we have obtained is sufficient andappropriate to provide a basis for our audit opinion.
OpinionIn our opinion, the financial statements and the related supplementaryschedules referred to above present fairly, in all material respects, thefinancial position and results of operations of the Organization
applicable to the second fiscal year ended March 31, 2014, in conformity
with accounting principles generally accepted in Japan for Public
Interest Incorporated Associations (equivalent to a 501(c)(3) in the
United States).
Conflicts of Interest
We have no interest in the Organization which should be disclosed incompliance with the Certified Public Accountants Act.
Ernst & Young ShinNihon LLC
May 7, 201414

Original letter in Japanese, submitted by Ernst & Young ShinNihon LLC.

2013 Financial Summary (audited, $USD)
SOURCES OF REVENUEREVENUE (in thousands)
Governments, NGOs,
multilateral organizations$10,693

Foundations

4,970

Corporations

4,863

TOTAL REVENUE

52.1% Governments, NGOs
multilateral organizations
24.2% Foundations
23.7% Corporations$20,526
EXPENSE ALLOCATION
97.4% Program services
2.6% Support services

EXPENSES (in thousands)
Program services$18,074

Support services

483

TOTAL EXPENSES$18,557

Assets, Liabilities, and Net Assets
ASSETS (in thousands)

GRANT INVESTMENTS (in $USD)

Cash and cash equivalents$8,169Fixed assets

2,452

TOTAL ASSETS$10,621BY DISEASE$4,283,887 MALARIA$6,175,472 TB$7,098,773 NTDs

LIABILITIES AND NET ASSETS (in thousands)
Total Liabilities$8,364BY INTERVENTION

Net Assets

2,257$10,112,580 DRUGS$7,445,552 VACCINESTOTAL LIABILITIES AND
NET ASSETS$10,621

The U.S. dollar amounts in this report represent translations ofJapanese yen, solely for the reader’s convenience, at ¥102.82=US$1,
the approximate exchange rate on March 31, 2014.

BY RESEARCH STAGE$8,844,761 PRE-CLINICAL$8,713,371 CLINICALThis financial summary is an excerpt from the GHIT Fund's audited
financial statements, which are audited by Ernst & Young ShinNihon
LLC. The GHIT Fund is a General Incorporated Association and isregistered in Japan.

15

LeadershipCouncilMembers of the Council
provide oversight for the
Board of Directors and serveas advocates for the GHIT
Fund’s mission. Our private
sector Council members are
not involved in organizationalor funding decisions. Funding
from the GHIT Fund need
not go to the same privatecompanies represented on
our Council. In fact, it may bedirected to a partnership withany institution in Japan. All
GHIT Fund grant investments
support partnerships between
Japanese entities and nonJapanese entities.

Takehiro Kagawa, Director-General, Global Issues, Ministry ofForeign Affairs, Government of Japan
Mitsuhiro Ushio, MD, Deputy Director-General for Global Health,
Minister’s Secretariat, Ministry of Health, Labour and Welfare,
Government of Japan
Trevor Mundel, MD, PhD, President, Global Health Program, Bill
& Melinda Gates Foundation
Astellas Pharma Inc.: Yoshihiko Hatanaka, Representative Director,
President and CEO
Daiichi Sankyo Company Ltd.: George Nakayama, Representative
Corporate Officer, President and CEO
Eisai Co. Ltd.: Haruo Naito, President and CEO
Shionogi & Co. Ltd.: Isao Teshirogi, PhD, President and CEO
Takeda Pharmaceutical Company Ltd.: Yasuchika Hasegawa,President and CEO

16

Board of Directors
The global health expertson the GHIT Fund’s Board of
Directors provide governanceand fiduciary oversight for
the Selection Committee, set
policy, and assess the GHIT
Fund’s overall performance.

Chair & Representative Director
Kiyoshi Kurokawa, MD, Academic Fellow, National Graduate
Institute for Policy Studies; Chairman, Health and Global Policy
InstituteExecutive Director
BT Slingsby, MD, PhD, MPH, CEO, Global Health Innovative
Technology Fund

Members

Peter Piot, MD, PhD, Director, London School of Hygiene & Tropical
Medicine, Former Executive Director of UNAIDS

Ann M. Veneman, Former Executive Director, UNICEF

Kazushi Yamauchi, MD, PhD, MPH, Director, International
Cooperation Office, International Affairs Division, Minister’s

Secretariat, Ministry of Health, Labour and Welfare, Government ofJapan

Hiroyuki Yamaya, Director, Global Health Policy Division,
International Cooperation Bureau, Ministry of Foreign Affairs,
Government of Japan

Advisors

Hikaru Ishiguro, LLM, Board Member and President, Health andGlobal Policy Institute
Ko-Yung Tung, JD, Senior Counselor, Morrison & Foerster LLP

Ex-Officio

Kim C. Bush, Director of Life Sciences Partnerships, Bill & Melinda
Gates Foundation17

Selection Committee
Members of the GHIT
Fund’s Selection Committee
evaluate grant proposals
and reports from grantees,
recommend the provision of
grants to Board of Directors,
and ensure independence,accountability andtransparency of the grant
review and recommendation
process. The Selection
Committee is free of large
pharma representatives
to avoid any conflicts ofinterest between our backers
and grantees.

Mahima Datla, Managing Director, Biological E. Ltd.
Ken Duncan, PhD, Deputy Director, Discovery & Translational
Sciences, Bill & Melinda Gates Foundation
Penny M. Heaton, MD, MPH, Director, Vaccine Development andSurveillance, Bill & Melinda Gates Foundation
Kiyoshi Kita, PhD, Professor and Chair, Department of Biomedical
Chemistry, Graduate School of Medicine, The University of Tokyo
Alex Matter, MD, CEO, Experimental Therapeutics Centre and D3,
A*STAR, Singapore
Yasuko Mori, MD, PhD, Professor, Division of Clinical Virology,
Center for Infectious Diseases, Kobe University Graduate School of
Medicine
Dennis Schmatz, PhD, Former head of Infectious Diseases Research,
Merck Research Labs, USA
Former Head of Research, MSD-Japan

Advisory Panel
Members provide strategic
advice to the Chair of theBoard and the CEO.

18

Peter Agre, MD, Director, Johns Hopkins Malaria Research Institute
Harvey V. Fineberg, MD, PhD, President, Institute of Medicine of
the National Academies
Dai Hozumi, MD, MSM, MPH, Senior Advisor for Health Systems
and Policy, PATH
Calestous Juma, PhD, Professor, Practice of International
Development and Director, Science, Technology, and Globalization
Project, Harvard Kennedy School
Michael R. Reich, PhD, Taro Takemi Professor of International
Health Policy, Harvard School of Public Health
Kumi Sato, President and CEO, Cosmo Public Relations Corporation
Peter Singer, MD, MPH, FRCPC, CEO, Grand Challenges Canada
and Director, Sandra Rotman Centre

External reviewers
The work of the GHIT community could not progress without vital support from these experts and their
institutions worldwide.

Dr. Richard Adegbola
Dr. Yukihiro Akeda
Dr. Pedro Alonso
Dr. Peter Andersen
Dr. W. Ripley Ballou
Dr. Clif Barry
Dr. Marleen Boelart
Dr. Maria Elena Bottazzi
Dr. Nancy Le Cam Bouveret
Dr. Tom Brewer
Dr. David Brown
Dr. Simon Campbell, CBE FRS
Dr. Shing Chang
Dr. Robert Chen
Dr. Simon Croft
Dr. Peter Dailey
Dr. Thomas Dick
Dr. Carter Diggs
Dr. Boro Dropulic
Dr. Filip Dubovsky
Dr. Hiroyoshi Endo
Dr. Alan Fairlamb
Dr. Hermann Feldmeier
Dr. Michael J. Free, OBE
Dr. Birgitte Giersing
Dr. Ann Ginsberg
Dr. Federico Gomez de las HerasDr. Glenda Gray
Dr. Brian Greenwood
Dr. Sanjay Gurunathan
Dr. R. Kiplin Guy
Dr. Lee Hall
Dr. Yoshihisa Hashiguchi
Dr. Chris Hentschel
Dr. Gray Heppner

Dr. Toshihiro Horii
Dr. Sanjay Jain
Dr. Nisha Jain Garg
Dr. Takushi Kaneko
Dr. Niranjan Kanesa-Thasan
Dr. Shigeyuki Kano
Dr. Gilla Kaplan
Dr. Subhash Kapre
Dr. Naoto Keicho
Dr. David Kelso
Dr. Kent Kester
Dr. Akinori Kimura
Dr. Sue Kinn
Dr. Somei Kojima
Dr. Rebecca Richards Kortum
Dr. Hidehito Kotani
Dr. Michael Kurilla
Dr. Dennis Kyle
Dr. James LeDuc
Dr. John Mansfield
Dr. Carol Marzetta
Dr. Greg Matlashewski
Dr. James McCarthy
Dr. Carl Mendel
Dr. Charles Mgone
Dr. Melinda Moree
Dr. Kouichi Morita
Dr. Charles Mowbray
Dr. Peter Myler
Dr. Daniel Neafsey
Dr. Christian Ockenhouse
Dr. Giuseppe Pantaleo
Dr. David Persing
Dr. Meg Phillips
Dr. Punnee Pitisuttithum

Dr. David Pompliano
Dr. Regina Rabinovich
Dr. Rino Rappuoli
Dr. Zarifah Reed
Dr. Yves Ribeill
Dr. Paul Roepe
Dr. Polly Roy
Dr. Peter Ruminski
Dr. Philip Russell
Dr. Judy SakanariDr. Hing ShamDr. George Siber
Dr. KJ Singh
Dr. Peter Smith
Dr. Lynn Soong
Dr. Dan Stinchcomb
Dr. Nathalie Strub-Wourgaft
Dr. Marcel TannerDr. Kaoru Terashima
Dr. Katsushi Tokunaga
Dr. Nadia G. Tornieporth
Dr. Bruno Travi
Dr. Takafumi Tsuboi
Dr. Moriya Tsuji
Dr. Mickey Urdea
Dr. Stephen Ward
Dr. Tim Wells
Dr. John Westwick
Dr. Bruce G. Weniger
Dr. Judith Wilber
Dr. Elizabeth Winzeler
Dr. Michael Witty
Dr. Paul Wyatt
Dr. Donato Zipeto

19

20

Thank you to our partners and sponsors
Partners

Japanese Ministry of Foreign Affairs
Japanese Ministry of Health, Labour and Welfare
Astellas Pharma Inc.
Daiichi Sankyo Company Ltd.
	Eisai Co. Ltd.
Shionogi & Co. Ltd.
	Takeda Pharmaceutical Company Ltd.
Bill & Melinda Gates Foundation
United Nations Development ProgrammeSponsors

Cosmo Public Relations Corporation
Mori Building Co. Ltd.

21

PARTNER WITH JAPAN,

ACCELERATE HEALTH INNOVATION

Ark Hills Sengokuyama Mori Tower 25F
1-9-10 Roppongi, Minato-ku
Tokyo 106-0032, Japan
TEL: +81-36441-2032 FAX: +81-36441-2031
www.ghitfund.org